IPRATROPIUM bromide nebuliser solution

Select language:
On this page


    Prescription under medical supervision


    Therapeutic action

    • Bronchodilator, anticholinergic drug


    • Acute life-threatening asthma attack, in combination with salbutamol

    Forms and strengths

    • Solution for inhalation, in unit dose vial of 0.25 mg in 1 ml (0.25 mg/ml) and 0.5 mg in 2 ml (0.25 mg/ml), to be administered via a nebuliser

    Dosage and duration

    • Child 1 month to < 12 years: 0.25 mg per nebulisation, to be repeated every 20 to 30 minutes if necessary
    • Child 12 years and over and adult: 0.5 mg per nebulisation, to be repeated every 20 to 30 minutes if necessary

    Contra-indications, adverse effects, precautions

    • May cause:
      • throat irritation, headache, cough, vomiting;
      • anticholinergic effects: dryness of the mouth, constipation, dilation of the pupils, blurred vision, urinary retention, tachycardia.
    • Administer with caution to elderly patients and patients with closed-angle glaucoma, benign prostatic hyperplasia, urinary retention.
    • Avoid or monitor combination with drugs known to have anticholinergic effects: tricyclic antidepressants (amitriptyline, clomipramine), H-1 antihistamines (chlorphenamine, promethazine), antiparkinsonians (biperiden), antispasmodics (atropine, hyoscine butylbromide), neuroleptics (chlorpromazine), etc. (increased risk of adverse effects).
    • Pregnancy: no contra-indication
    • Breast-feeding: no contra-indication


    • Volumes of nebuliser solution to be administered are insufficient to obtain efficient nebulisation in most nebulisers: add ipratropium to salbutamol and then 0.9% sodium chloride to obtain a total volume of 5 ml in the reservoir of the nebuliser. Stop the nebulisation when the reservoir is empty, after around 10 to 15 minutes.


    - Below 25 °C